Vasomotor Symptoms of Menopause - Pipeline Insight, 2024

Vasomotor Symptoms of Menopause - Pipeline Insight, 2024

DelveInsight’s, “Vasomotor Symptoms of Menopause - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Vasomotor Symptoms of Menopause pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vasomotor Symptoms of Menopause Understanding

Vasomotor Symptoms of Menopause: Overview

Vasomotor symptoms (VMS) or hot flashes and night sweats, are hallmarks of the menopausal transition (MT) and can significantly affect quality of life. Up to 80% of women experience VMS during menopause 5,6 and a majority of women rate them as moderate-to-severe. The cause of hot flashes is not fully understood and is likely multifactorial. It is generally thought that hot flashes result from a narrowing of the thermoneutral zone in perimenopausal women. Reproductive hormones play an important role in this narrowing, given that the onset of VMS corresponds to changes in reproductive hormones at the menopausal transition and the therapeutic effect of exogenous estrogen.

The cause of hot flushes has yet to be determined because of the limited research focus in this therapeutic area. Hot flushes are believed to result from the brain's response to diminished hormones and hormonal fluctuations that occur during the menopausal transition. Ovarian hormones have been shown to influence thermoregulatory mechanisms that regulate temperature homeostasis in the hypothalamus. The neurotransmitters serotonin and norepinephrine play a role in modulating core body temperature, neurochemical messaging, and peripheral vasculature.

Smoking is the primary health behavior that has been associated with VMS. SWAN has shown that both active smoking and passive smoke exposure are related to greater likelihood of VMS. Physical activity, diet, and alcohol consumption are other health behaviors people have studied, but these results are weak and inconsistent. In contrast to the inconsistent role of lifestyle factors, studies have shown that psychosocial factors such as anxiety and depression are more consistently associated with VMS.

Hot flashes are a common VMS of menopause. Other symptoms include sweating, including night sweats, sleep disturbances, anxiety, heart palpitations. These symptoms tend to affect people for about a year. But 17% of women may continue to experience them for several years.

Multiple forms of treatment have been used to relieve hot flashes, including lifestyle modifications, non-prescription drugs, and prescription drugs. Prescription drugs may be grouped into hormonal and non-hormonal agents. Progestogens alone may be considered as an alternative for treating hot flashes if the benefit–risk profile is acceptable to the woman. Hormone therapy aims to balance hormone levels in the body. It can help relieve hot flashes and other symptoms. Antidepressants, such as paroxetine (Paxil), may help. Healthcare professionals will usually prescribe a lower dosage for menopause symptoms.

""Vasomotor Symptoms of Menopause - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasomotor Symptoms of Menopause pipeline landscape is provided which includes the disease overview and Vasomotor Symptoms of Menopause treatment guidelines. The assessment part of the report embraces, in depth Vasomotor Symptoms of Menopause commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasomotor Symptoms of Menopause collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor Symptoms of Menopause R&D. The therapies under development are focused on novel approaches to treat/improve Vasomotor Symptoms of Menopause.

Vasomotor Symptoms of Menopause Emerging Drugs Chapters

This segment of the Vasomotor Symptoms of Menopause report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasomotor Symptoms of Menopause Emerging Drugs

• Elinzanetant: Bayer

Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes. The drug is currently being investigated in Phase III clinical trial OASIS, which aims to evaluate the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms during menopause.

• FP-101: Fervent Pharmaceuticals

FP-101 is an oral formulation of an existing compound that is FDA approved for another indication. It is being developed by Fervent Pharmaceuticals for the treatment of vasomotor symptoms associated with menopause, such as hot flashes, night sweats, and insomnia. The compound is non-hormonal, non-herbal, non-antidepressant, and has a long history of safe use. The Drug is currently in Phase II stage of its clinical development for the treatment of Vasomotor Symptoms of Menopause.

Further product details are provided in the report……..

Vasomotor Symptoms of Menopause: Therapeutic Assessment

This segment of the report provides insights about the different Vasomotor Symptoms of Menopause drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vasomotor Symptoms of Menopause

There are approx. 8+ key companies which are developing the therapies for Vasomotor Symptoms of Menopause. The companies which have their Vasomotor Symptoms of Menopause drug candidates in the most advanced stage, i.e. phase III include, Bayer.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Vasomotor Symptoms of Menopause pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasomotor Symptoms of Menopause: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor Symptoms of Menopause therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor Symptoms of Menopause drugs.

Vasomotor Symptoms of Menopause Report Insights

• Vasomotor Symptoms of Menopause Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vasomotor Symptoms of Menopause Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vasomotor Symptoms of Menopause drugs?
• How many Vasomotor Symptoms of Menopause drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasomotor Symptoms of Menopause?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasomotor Symptoms of Menopause therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vasomotor Symptoms of Menopause and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bayer
• Fervent Pharmaceuticals
• Mitsubishi Tanabe Pharma
• MenoGeniX, Inc.
• Mithra Pharmaceuticals
• Vistagen Therapeutics

Key Products

• Elinzanetant
• FP-101
• MT-8554
• MNGX-100
• Estetrol
• PH80